Working… Menu

Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01782976
Recruitment Status : Withdrawn
First Posted : February 4, 2013
Last Update Posted : January 19, 2018
Brain Tumor Trials Collaborative
EMD Serono
Information provided by (Responsible Party):
M.D. Anderson Cancer Center

No Study Results Posted on for this Study
Study was withdrawn before participants were enrolled.
Recruitment Status : Withdrawn
Estimated Primary Completion Date : June 2017
Study Completion Date : No date given